Effects of dose and duration of anti-CD154 antibody therapy in preventing renal allograft rejection in a nonhuman primate model

Transplantation Proceedings

Volumn 33, Issue 1-2, 2001, Pages 223-224

  Xu, H ^a   Elster, E ^a   Batty, D ^b   Berning, J ^a   Burkly, L ^c   Kampen, R ^a   Swanson, S ^b   Tadaki, D ^a   Harlan, D ^a   Kirk, A ^a,b,d  

^a NAVAL MEDICAL RESEARCH CENTER   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c BIOGEN   (United States)

^d Building 10 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5C8; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; MAINTENANCE THERAPY; MONITORING; NONHUMAN; PRIMATE; PRIORITY JOURNAL; RHESUS MONKEY; SURVIVAL;

ANIMALS; ANTIBODIES, MONOCLONAL; CD40 LIGAND; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; GRAFT REJECTION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MACACA MULATTA; MYCOPHENOLIC ACID;

EID: 0035084115     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0041-1345(00)01983-7     Document Type: Conference Paper

References (3)

1. Kirk AD, Burkly LC, Batty DS, et al: Nat Med 5:686, 1999
2. Kenyon NS, Chatzipetrou M, Masetti M, et al: Proc Natl Acad Sci USA 96:8132, 1999
3. Kirk AD, Harlan DM, Armstrong NN, et al: Proc Natl Acad Sci USA 94:8789, 1997